Table 1 Patient characteristics
HCC (n = 187) | PDAC (n = 162) | |
|---|---|---|
Age, mean ± SD [years] | 63.3 ± 13.8 | 65.4 ± 10.8 |
Gender, m/f [n] | 105/82 | 92/70 |
1Tumor grade [n (%)] | ||
G1 | 34 (18.6) | 28 (17.4) |
G2 | 102 (55.7) | 84 (52.2) |
G3 | 46 (25.1) | 47 (29.2) |
G4 | 1 (0.5) | 2 (1.2) |
2Tumor stage [n (%)] | ||
I | 80 (47.3) | 20 (12.6) |
II | 44 (26.0) | 130 (81.8) |
III | 41 (24.3) | 4 (2.5) |
IV | 4 (2.4) | 5 (3.1) |
Specific PFI | ||
median observation period (mo) | 12.0 | 12.1 |
event / censored [n(%)] | 99 (52.9) / 88 (47.1) | 93 (57.4) / 69 (42.6) |
median specific PFI (mo) | 19.7 | 16.2 |
OS time | ||
median observation period (mo) | 22.1 | 15.3 |
event / censored [n(%)] | 77 (41.2) / 110 (58,8) | 86 (53.1) / 76 (46.9) |
median OS (mo) | 45.9 | 20.2 |
IFNL3 genotypes | ||
rs4803217 CC:CA:AA [n(%)] | 79 (42.2): 89 (47.6): 19 (10.2) | – |
rs28416813 CC:CG:GG [n(%)] | – | 76 (46.9): 69 (42.6): 17 (10.5) |
MAF | 0.340 | 0.318 |
HWE | p = 0.40 | p = 0.82 |